Conceptual approaches and the current state of the atherosclerosis treatment in Ukraine
DOI:
https://doi.org/10.24959/nphj.25.180Keywords:
atherosclerosis; antilipidemic and antiatherosclerotic medicine; pharmaceutical market analysis; efficacy; safety; search directionsAbstract
Aim. To study the range of medicines for the pharmacotherapy of atherosclerosis and determine the latest approaches to the treatment of atherosclerosis using drugs with a combined mechanism of action.
Materіals and methods. The study objects in this work were antiatherosclerotic medicines. The work used a logical, systematic, and structural analysis of scientific sources, taking into account their main pharmacological characteristics (the mechanism of action, effectiveness, side effects, etc.), their trade names, manufacturing countries, dosage forms, etc. To search for medicines, an information system, including the State Register of Medicinal Products, “Drug Control”, Clinical protocols for medical care and prevention of atherosclerosis and other cardiovascular diseases, as well as Rx Index, Compendium etc., was used.
Results. The paper provides information on the study of the range of medicines for the treatment of atherosclerosis in the pharmaceutical market of Ukraine and the prospects for finding new drugs of this group with different mechanisms of action. According to the results of the study, the ratio of domestic and foreign-produced medicines presented in the pharmaceutical market of Ukraine has been determined. It has been found that the share of domestic medicines is only about 11 %, which determines the need to expand their range. They are mainly available in the form of tablets, capsules and solutions for injections. Therefore, the range of dosage forms is limited and also needs to be expanded for the convenience of using the drugs. The pharmacological features of the main groups of drugs used to treat atherosclerosis (statins, fibrates, cholesterol absorption inhibitors, PCSK9 inhibitors, bile acid sequestrants, angioprotectors, antioxidants, etc.) are described. Their mechanism of action, complications of pharmacotherapy and ways to overcome them through to overcome the combination therapy are highlighted. Prospects for the search for new drugs for the treatment of atherosclerosis are presented.
Conclusions. According to the results of the studies conducted, it has been found that in the pharmaceutical market of Ukraine, most of the medicines for the treatment of atherosclerosis are of foreign production. Their import substitution with effective and safe medicines is one of the tasks of modern pharmacy. Taking into account the individual characteristics of patients provides more effective and safe treatment. The main areas of the search for new medicines are the creation of combined drugs, the use of the latest innovative drugs, and the combination therapy using medicines of natural origin.
References
Manoilenko, T. S., Kyrychenko, A. H., Kornatskyi, Yu. V., Handziuk, V. A., Revenko, I. L., & Bieliaieva, T. V. (2024). Dynamika stanu zdorovia naselennia v umovakh viiny v Ukraini: posibnyk. Vydavets O. V. Tretiakov.
Sertsevo-sudynni zakhvoriuvannia v Ukraini: prohnozy ‒ nevtishni. (2015, Sichen 9). Vashe zdorovia. https://www.vz.kiev.ua/sercevo-sudinni-zaxvoryuvannya-v-ukrayini-prognozi-nevtishni/
Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy. (2022). Clinical Trials, 19(6), 593–604. http://doi.org/10.1177/17407745221105509
Kovtun, H. I., & Orlova, N. M. (2023). Smertnist vid khvorob systemy krovoobihu v Ukraini: medyko-statystychnyi analiz yii dynamiky ta rehionalnykh osoblyvostei u 2010-2020 rr. Visnyk Vinnytskoho natsionalnoho medychnoho universytetu, 27(1), 110–118.
Sertsevo-sudynni zakhvoriuvannia. https://www.bsmu.edu.ua/blog/serczevo-sudinni-zahvoryuvannya/
Arterialna hipertenziia. Tsentr hromadskoho zdorovia MOZ Ukrainy. https://phc.org.ua/kontrol-zakhvoryuvan/neinfekciyni-zakhvoryuvannya/sercevo-sudinni-zakhvoryuvannya/arterialna-gipertenziya/
Sertsevo-sudynni zakhvoriuvannia – holovna prychyna smerti ukraintsiv. Tsentr hromadskoho zdorovia MOZ Ukrainy. https://phc.org.ua/news/sercevo-sudinni-zakhvoryuvannya-golovna-prichina-smerti-ukrainciv-visnovki-z-doslidzhennya/
Cardiovascular diseases. World Health Organization. https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1/
Liky vid aterosklerozu. https://liki24.com/uk/category/8000766/
Derzhavnyi reiestr likarskykh zasobiv Ukrainy. http://www.drlz.com.ua/ibp/ddsite.nsf/ all/shlist?opendocument&atscode=R05
Derzhavnyi formuliar likarskykh zasobiv. https://www.dec.gov.ua/materials/chynnyj-vypusk-derzhavnogo-formulyara-likarskyh-zasobiv/
Lik Kontrol. https://likicontrol.com.ua/%D0%BF%D0%BE%D1%88%D1%83%D0%BA-%D0%BB%D1%96%D0%BA%D1%96%D0%B2/
ATKh klasyfikatsiia likarskykh zasobiv. https://rx.ua/atc-ath
Nakaz MOZ Ukrainy «Unifikovanyi Klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy. Profilaktyka sertsevo-sudynnykh zakhvoriuvan» № 564 (2016, Cherven 13). https://www.dec.gov.ua/wp-content/uploads/2019/11/2016_564_ykpmd_pssz.pdf
Nakaz MOZ Ukrainy «Unifikovanyi Klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy. Hipertonichna khvoroba (arterialna hipertenziia)» № 1581 (2024, Veresen 15). https://www.dec.gov.ua/wp-content/uploads/2024/09/ykpmd_1581_12092024_dod.pdf
Kovalenko, V. M. (Red.). (2019). Kompendium 2019 – likarski preparaty. Morion.
Radomychelski, I. M., Piddubnyi, A., Domashenko, M., & Moskalenko, R. (2021). Patohistolohichni zminy aterosklerotychnoi aorty yak biomekhanichni ryzyky porushennia tsilisnosti yii stinky. Visnyk problem biolohii i medytsyny, 4(162), 285–290.
Frampton, J. E. (2023). Inclisiran: A Review in Hypercholesterolemia. Am J. Cardiovasc Drugs, 23(2), 219–230.
Ahmadi, A., Argulian, E., Leipsic, J. Newby, D. E., & Narula, J. (2019). From Subclinical Atherosclerosis to Plaque Progression and Acute Coronary Events: JACC State-of-the-Art Review. J. Am Coll Cardiol, 74(12), 1608–1617.
Merkel, M. (2023). Hypercholesterinämie – Wen, wann, wie behandeln? Dtsch. Med. Wochenschr, 148(17), 1088–1094.
Drohovoz, S. M. (2017). Farmakolohiia na dopomohu likariu, provizoru, studentu: dovidnyk. Natsionalnyi farmatsevtychnyi universytet.
Davydovych, O. V., Prykhodko, V. Yu., Davydovych, N. Ya., & Poshtaruk, M. V. (2010). Pryntsypy medykamentoznoho likuvannia aterosklerozu. Ratsionalna farmakoterapiia, 2(15), 37–40.
Ray, K. K., Corral, P., Morales, E., & Nicholls, S. J. (2019). Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: Current and future options. Lancet, 394, 697–708.
Tsimikas, S., Gordts, P., Nora, C., Yeang, C., & Witztumet, J. L. (2020). Statin therapy increases lipoprotein(a) levels. Eur. Heart J., 41(24), 2275–2284.
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., De Mets, D., Evans, S., Law, M., MacMahon, S., Martin, S., Neal, B., Poulter, N., Preiss, D., Ridker, P., Roberts, I., . . . . Peto, R. (2016). Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet, 388(10059), 2532–2561.
Gao, A., Cayabyab, F. S., Chen, X., Yang, J., Wang, L., Peng, T., & Yuncheng, L. (2017). Implications of Sortilin in Lipid Metabolism and Lipid Disorder Diseases. DNA Cell. Biol., 36(12), 1050–1061.
Holmes, M. V., Millwood, I. Y., Kartsonaki, C., Hill, M. R., Bennett, D. A., Boxall, R., Guo, Y., Xu, X., Bian, Z., Hu, R., Walters, R. G., Chen, J., Ala-Korpela, M., Parish, S., Clarke, R. J., Peto, R., Collins, R., Li, L., & Chen, Z. (2018). Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke. J. Am. Coll. Cardiol., 71(6), 620–632.
Nissen, S. E., Lincoff, A. M., Brennan, D., Ray, K. K., Mason, D., Kastelein, J. J., Thompson, P. D., Libby, P., Cho, L., Plutzky, J., Bays, H. E., Moriarty, P. M., Menon, V., Grobbee, D. E., Louie, M. J., Chen, C.-F., Li, N., Bloedon, L., Robinson, P., . . . Nicholls, S. J. (2023). Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N. Engl. J. Med., 388(15), 1353–1364.
Kayani, T., Ahmad, B., Chang, R. S., Frank, Q., Melis, S., Muhammad, R., Antonio G., Spatz, E., & Jiun-Ruey, H. (2024). Beyond Statins: Novel Lipid-Lowering Agents for Reducing Risk of Atherosclerotic Cardiovascular Disease. Pharmacoepidemiology, 3(1), 117–168.
Ateroskleroz. Kompendium. Likarski preparaty Ukrainy. https://compendium.com.ua/uk/tutorials-uk/vnutrishnya-meditsina/2-rozdil-zakhvoriuvannia-sertsia-ta-sudyn/2-1-ateroskleroz/
Ateroskleroz. Natsionalnyi tsentr biotekhnolohichnoi informatsii. https://www.ncbi.nlm.nih.gov/
Shkodyt zdoroviu ne sam kholesteryn, a yoho nadlyshok. Tsentr hromadskoho zdorovia MOZ Ukrainy. https://phc.org.ua/news/shkodit-zdorovyu-ne-sam-kholesterin-yogo-nadlishok-poyasnyue-simeyna-likarka/
Libby, P., Buring, J. E., Badimon, L., Hansson, G. K., Deanfield, J., Bittencourt, M. S., Tokgözoğlu, L., & Lewis, E. F. (2019). Atherosclerosis. Nat. Rev. Dis. Primers, 5(1), 56.
Yahagi, K., Kolodgie, F. D., Lutter, C., Mori, H., Romero, M. E., Finn, A. V., & Virmani, R. (2017). Pathology of Human Coronary and Carotid Artery Atherosclerosis and Vascular Calcification in Diabetes Mellitus. Arterioscler. Thromb. Vasc. Biol., 37(2), 191–204.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
